Articles

Neovacs and Stellar Biotechnologies announce launch of Neostell

The new joint venture is designed to manufacture kinoids; first moves included appointment of administrative board and management team appointed
Brought to you byDDNews Staff
| 2 min read

PARIS, BOSTON & PORT HUENEME, Calif.—July 19 saw Neovacs and Stellar Biotechnologies Inc. announce the start of their joint venture company, Neostell SAS, with the holding of its first general assembly. At the meeting, the bylaws for Neostell were approved and the administrative board and management team were appointed.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.